Clinical Trials Browser

GSK 1363089 × Clear all

NCT01138384 2023-08-04

Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

Phase 1/2 Completed

Breast Neoplasms

NCT01147484 2023-08-04

IND197

Phase 2 Completed

Breast Neoplasms

NCT00726323 2017-12-11

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Phase 2 Completed

74 enrolled 14 charts

Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT00725764 2017-10-16

Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

Phase 2 Completed

14 enrolled 14 charts

Head and Neck Neoplasms

NCT00725712 2017-08-24

Study of GSK1363089 in Metastatic Gastric Cancer

Phase 2 Completed

74 enrolled 22 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT00742131 2017-07-31

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumours

NCT00743067 2017-07-26

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumours

NCT00920192 2017-07-18

Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer

Phase 1 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT00742261 2017-07-07

A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumours

NCT02034097 2014-05-19

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasms